These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
516 related articles for article (PubMed ID: 23053650)
1. Investigation of elemene-induced reversal of tamoxifen resistance in MCF-7 cells through oestrogen receptor α (ERα) re-expression. Zhang B; Zhang X; Tang B; Zheng P; Zhang Y Breast Cancer Res Treat; 2012 Nov; 136(2):399-406. PubMed ID: 23053650 [TBL] [Abstract][Full Text] [Related]
2. Mechanisms of Gefitinib-mediated reversal of tamoxifen resistance in MCF-7 breast cancer cells by inducing ERα re-expression. Zhang X; Zhang B; Liu J; Liu J; Li C; Dong W; Fang S; Li M; Song B; Tang B; Wang Z; Zhang Y Sci Rep; 2015 Feb; 5():7835. PubMed ID: 25644501 [TBL] [Abstract][Full Text] [Related]
3. Keratinocyte growth factor (KGF) induces tamoxifen (Tam) resistance in human breast cancer MCF-7 cells. Chang HL; Sugimoto Y; Liu S; Ye W; Wang LS; Huang YW; Lin YC Anticancer Res; 2006; 26(3A):1773-84. PubMed ID: 16827106 [TBL] [Abstract][Full Text] [Related]
4. Potential of endogenous estrogen receptor beta to influence the selective ER modulator ERbeta complex. Chen B; Gajdos C; Dardes R; Kidwai N; Johnston SR; Dowsett M; Jordan VC Int J Oncol; 2005 Aug; 27(2):327-35. PubMed ID: 16010412 [TBL] [Abstract][Full Text] [Related]
5. Inducible upregulation of oestrogen receptor-beta1 affects oestrogen and tamoxifen responsiveness in MCF7 human breast cancer cells. Murphy LC; Peng B; Lewis A; Davie JR; Leygue E; Kemp A; Ung K; Vendetti M; Shiu R J Mol Endocrinol; 2005 Apr; 34(2):553-66. PubMed ID: 15821116 [TBL] [Abstract][Full Text] [Related]
6. Long-term treatment with tamoxifen facilitates translocation of estrogen receptor alpha out of the nucleus and enhances its interaction with EGFR in MCF-7 breast cancer cells. Fan P; Wang J; Santen RJ; Yue W Cancer Res; 2007 Feb; 67(3):1352-60. PubMed ID: 17283173 [TBL] [Abstract][Full Text] [Related]
7. Estrogen receptor-α variant, ER-α36, is involved in tamoxifen resistance and estrogen hypersensitivity. Zhang X; Wang ZY Endocrinology; 2013 Jun; 154(6):1990-8. PubMed ID: 23546601 [TBL] [Abstract][Full Text] [Related]
8. Arsenic trioxide re-sensitizes ERα-negative breast cancer cells to endocrine therapy by restoring ERα expression in vitro and in vivo. Zhang W; Wang L; Fan Q; Wu X; Wang F; Wang R; Ma Z; Yang J; Lu SH Oncol Rep; 2011 Sep; 26(3):621-8. PubMed ID: 21687957 [TBL] [Abstract][Full Text] [Related]
9. Bidirectional cross talk between ERalpha and EGFR signalling pathways regulates tamoxifen-resistant growth. Britton DJ; Hutcheson IR; Knowlden JM; Barrow D; Giles M; McClelland RA; Gee JM; Nicholson RI Breast Cancer Res Treat; 2006 Mar; 96(2):131-46. PubMed ID: 16261397 [TBL] [Abstract][Full Text] [Related]
10. Androgen receptor promotes tamoxifen agonist activity by activation of EGFR in ERα-positive breast cancer. Ciupek A; Rechoum Y; Gu G; Gelsomino L; Beyer AR; Brusco L; Covington KR; Tsimelzon A; Fuqua SA Breast Cancer Res Treat; 2015 Nov; 154(2):225-37. PubMed ID: 26487496 [TBL] [Abstract][Full Text] [Related]
11. Growth of hormone-dependent MCF-7 breast cancer cells is promoted by constitutive caveolin-1 whose expression is lost in an EGF-R-mediated manner during development of tamoxifen resistance. Thomas NB; Hutcheson IR; Campbell L; Gee J; Taylor KM; Nicholson RI; Gumbleton M Breast Cancer Res Treat; 2010 Feb; 119(3):575-91. PubMed ID: 19288272 [TBL] [Abstract][Full Text] [Related]
12. Reversal of ER-β silencing by chromatin modifying agents overrides acquired tamoxifen resistance. Pitta CA; Papageorgis P; Charalambous C; Constantinou AI Cancer Lett; 2013 Sep; 337(2):167-76. PubMed ID: 23752064 [TBL] [Abstract][Full Text] [Related]
14. Long Non-Coding RNA H19 Acts as an Estrogen Receptor Modulator that is Required for Endocrine Therapy Resistance in ER+ Breast Cancer Cells. Basak P; Chatterjee S; Bhat V; Su A; Jin H; Lee-Wing V; Liu Q; Hu P; Murphy LC; Raouf A Cell Physiol Biochem; 2018; 51(4):1518-1532. PubMed ID: 30497079 [TBL] [Abstract][Full Text] [Related]
15. Expression of the CD59 Glycoprotein Precursor is Upregulated in an Estrogen Receptor-alpha (ER-α)-Negative and a Tamoxifen-Resistant Breast Cancer Cell Line In Vitro. Xiong H; Jin X; You C Med Sci Monit; 2018 Nov; 24():7883-7890. PubMed ID: 30391994 [TBL] [Abstract][Full Text] [Related]
16. Identification of Sirtuin 3, a mitochondrial protein deacetylase, as a new contributor to tamoxifen resistance in breast cancer cells. Zhang L; Ren X; Cheng Y; Huber-Keener K; Liu X; Zhang Y; Yuan YS; Yang JW; Liu CG; Yang JM Biochem Pharmacol; 2013 Sep; 86(6):726-33. PubMed ID: 23856293 [TBL] [Abstract][Full Text] [Related]
17. Influence of oestradiol and tamoxifen on oestrogen receptors-alpha and -beta protein degradation and non-genomic signalling pathways in uterine and breast carcinoma cells. Horner-Glister E; Maleki-Dizaji M; Guerin CJ; Johnson SM; Styles J; White IN J Mol Endocrinol; 2005 Dec; 35(3):421-32. PubMed ID: 16326830 [TBL] [Abstract][Full Text] [Related]
18. Inhibition of proliferation of estrogen receptor‑positive MCF‑7 human breast cancer cells by tamoxifen through c‑Jun transcription factors. Xu Y; Zou ST; Zhu R; Li W; Gu CW; Wei SH; Xie JM; Wu HR Mol Med Rep; 2013 Apr; 7(4):1283-7. PubMed ID: 23404426 [TBL] [Abstract][Full Text] [Related]
19. Reversal of tamoxifen resistant breast cancer by low dose estrogen therapy. Osipo C; Gajdos C; Cheng D; Jordan VC J Steroid Biochem Mol Biol; 2005 Feb; 93(2-5):249-56. PubMed ID: 15860267 [TBL] [Abstract][Full Text] [Related]
20. Oestrogen receptor-mediated modulation of the EGFR/MAPK pathway in tamoxifen-resistant MCF-7 cells. Hutcheson IR; Knowlden JM; Madden TA; Barrow D; Gee JM; Wakeling AE; Nicholson RI Breast Cancer Res Treat; 2003 Sep; 81(1):81-93. PubMed ID: 14531500 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]